ID: ALA4202574

Max Phase: Preclinical

Molecular Formula: C26H24ClN3O2

Molecular Weight: 445.95

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1N(CCCCc2cc3cc(-c4ccc(Cl)cc4)ccc3o2)CCN1c1ccncc1

Standard InChI:  InChI=1S/C26H24ClN3O2/c27-22-7-4-19(5-8-22)20-6-9-25-21(17-20)18-24(32-25)3-1-2-14-29-15-16-30(26(29)31)23-10-12-28-13-11-23/h4-13,17-18H,1-3,14-16H2

Standard InChI Key:  CSXAQLNHDLZWGI-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 445.95

Molecular Weight (Monoisotopic): 445.1557

AlogP: 6.41

#Rotatable Bonds: 7

Polar Surface Area: 49.58

Molecular Species: NEUTRAL

HBA: 3

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 4.48

CX LogP: 4.88

CX LogD: 4.88

Aromatic Rings: 4

Heavy Atoms: 32

QED Weighted: 0.31

Np Likeness Score: -0.98

References

1. Li P, Yu J, Hao F, He H, Shi X, Hu J, Wang L, Du C, Zhang X, Sun Y, Lin F, Gu Z, Xu D, Chen X, Shen L, Hu G, Li J, Chen S, Xiao W, Wang Z, Guo Q, Chang X, Tian X, Lin T..  (2017)  Discovery of Potent EV71 Capsid Inhibitors for Treatment of HFMD.,  8  (8): [PMID:28835799] [10.1021/acsmedchemlett.7b00188]

Source

Source(1):

• Scientific Literature